Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy

키워드

참고문헌 (33)

1. Kornbluth A, "Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee", Am J Gastroenterol, 105, pp.501~523 (2010)
2. Ordás I, "Ulcerative colitis", Lancet, 380, pp.1606~1619 (2012)
3. Mowat C, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 60, pp.571~607 (2011)
4. Baldassano RN, "Inflammatory bowel disease in pediatric and adolescent patients", Gastroenterol Clin North Am, 28, pp.445~458 (1999)
5. Dotson JL, "Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity", J Pediatr Gastroenterol Nutr, 51, pp.140~145 (2010)
6. Van Limbergen J, "Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease", Gastroenterology, 135, pp.1114~1122 (2008)
7. Sylvester FA, "Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis", Inflamm Bowel Dis, 17, pp.1726~1730 (2011)
8. Griffiths AM, "Specificities of inflammatory bowel disease in childhood", Best Pract Res Clin Gastroenterol, 18, pp.509~523 (2004)
9. Ruemmele FM, "Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis", J Crohns Colitis, 8, pp.1~4 (2014)
10. Turner D, "Management of pediatric ulcerative colitis : joint ECCO and ESPGHAN evidence-based consensus guidelines", J Pediatr Gastroenterol Nutr, 55, pp.340~361 (2012)
11. Ford AC, "Efficacy of biological therapies in inflammatory bowel disease : systematic review and meta-analysis", Am J Gastroenterol, 106, pp.644~659 (2011)
12. Turner D, "Severe paediatric ulcerative colitis : incidence, outcomes and optimal timing for second-line therapy", Gut, 57, pp.331~338 (2008)
13. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, "Inflammatory bowel disease in children and adolescents : recommendations for diagnosis--the Porto criteria", J Pediatr Gastroenterol Nutr, 41, pp.1~7 (2005)
14. Turner D, "Response to corticosteroids in severe ulcerative colitis : a systematic review of the literature and a meta-regression", Clin Gastroenterol Hepatol, 5, pp.103~110 (2007)
15. Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
16. Amin J, "Update 2014 : advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD", Inflamm Bowel Dis, 21, pp.445~452 (2015)
17. Lee MN, "Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine", Inflamm Bowel Dis, 21, pp.1054~1062 (2015)
18. 김미진, "Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease", Pediatric Gastroenterology, Hepatology & Nutrition, 16(2), pp.65~70 (2013), 대한소아소화기영양학회
19. Travis SP, "Developing an instrument to assess the endoscopic severity of ulcerative colitis : the Ulcerative Colitis Endoscopic Index of Severity(UCEIS)", Gut, 61, pp.535~542 (2012)
20. Travis SP, "Reliability and initial validation of the ulcerative colitis endoscopic index of severity", Gastroenterology, 145, pp.987~995 (2013)
21. Hyams JS, "Clinical outcome of ulcerative colitis in children", J Pediatr, 129, pp.81~88 (1996)
22. Jakobsen C, "Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study", Aliment Pharmacol Ther, 34, pp.1217~1224 (2011)
23. McManus R, "Mechanisms of steroid action and resistance in inflammation and disease", J Endocrinol, 178, pp.1~4 (2003)
24. Bianchi Porro G, "Review article : the management of steroid dependency in ulcerative colitis", Aliment Pharmacol Ther, 26, pp.779~794 (2007)
25. Danese S, "Mechanisms of action of infliximab in inflammatory bowel disease : an anti-inflammatory multitasker", Dig Liver Dis, 40(Suppl 2), pp.S225~S228 (2008)
26. Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
27. Järnerot G, "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis : a randomized, placebo-controlled study", Gastroenterology, 128, pp.1805~1811 (2005)
28. Turner D, "Severe pediatric ulcerative colitis : a prospective multicenter study of outcomes and predictors of response", Gastroenterology, 138, pp.2282~2291 (2010)
29. Hyams J, "Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis", Clin Gastroenterol Hepatol, 10, pp.391~399 (2012)
30. Sandborn WJ, "What’s new : innovative concepts in inflammatory bowel disease", Colorectal Dis, 8(Suppl 1), pp.3~9 (2006)
31. Matula S, "Chemoprevention of colorectal neoplasia in ulcerative colitis : the effect of 6-mercaptopurine", Clin Gastroenterol Hepatol, 3, pp.1015~1021 (2005)
32. Tajiri H, "Infliximab for pediatric patients with ulcerative colitis : a phase 3, openlabel, uncontrolled, multicenter trial in Japan", BMC Pediatr, 19, pp.351~ (2019)
33. Adedokun OJ, "Pharmacokinetics of infliximab in children with moderate-tosevere ulcerative colitis : results from a randomized, multicenter, open-label, phase 3 study", Inflamm Bowel Dis, 19, pp.2753~2762 (2013)

관련 논문AI추천